External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Roche and Genentech at

WMS 2023

-
Coming soon
02:30 PM
Duration 1hr Charleston, USA
Safety update: Risdiplam▼ clinical trial program for spinal muscular atrophy (SMA)
G Baranello, CA Chiriboga, L Servais, BT Darras, JW Day, NDeconinck, MA Farrar, RS Finkel, E Bertini, J Kirschner, R Masson, M Mazurkiewicz-Bełdzińska, D Vlodavets, S Bader-Weder, K Gorni, B Jaber, T McIver, G Papp, RS Scalco, E Mercuri

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 1hr Charleston, USA
Bioavailability and bioequivalence of risdiplam▼ tablets in healthy volunteers
H Kletzl, K Heinig, B Jaber, B Lomeli, WY Yeung, H Coleman, D Morrison

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 1hr Charleston, USA
MANATEE: GYM329 (RO7204239) in combination with risdiplam▼ treatment in patients with spinal muscular atrophy (SMA)
T Duong, BT Darras, J Morrow, F Muntoni, L Servais, M Rabbia, M Gerber, H Kletzl, E Gaki, S Fletcher, RS Scalco, K Wagner, E Mercuri

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 1hr Charleston, USA
EMBARK, a Phase 3 trial evaluating safety and efficacy of delandistrogene moxeparvovec in DMD: Study design and baseline characteristics
Muntoni F, Mercuri E, Schara-Schmidt U, Komaki H, Richardson J,Singh T, Guridi M, Mason S, Murphy AP, Yu L, Reid C, Darton E, Wandel C, Mendell JR

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 1hr Charleston, USA
ENVISION, a Phase 3, randomized trial evaluating the safety and efficacy of delandistrogene moxeparvovec in Duchenne muscular dystrophy: Study design
F Muntoni, E Mercuri, C McDonald, I Desguerre, Ma Tulinius, C Proud, M Furgerson, A P. Murphy, C De Ford, T Feng, C Reid, C Wandel, N Shelton

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 1hr Charleston, USA
ENVOL, a Phase 2, open-label trial evaluating the safety and expression of delandistrogene moxeparvovec in Duchenne muscular dystrophy: Study design
E Mercuri, I Desguerre, A Gangfuss, L Servais, A Nascimento, B B Zhang, A P. Murphy, C Reid, C Wandel, Teji Singh, M Guridi, F Muntoni

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 1hr Charleston, USA
Practical considerations for delandistrogene moxeparvovec gene therapy in patients with Duchenne muscular dystrophy
JR Mendell, C Proud, C Zaidman, S Mason, E Darton, C Wandel, A Murphy, E Mercuri, F Muntoni, C McDonald

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 1hr Charleston, USA
T-cell response to micro-dystrophin in a patient treated with delandistrogene moxeparvovec gene therapy: A case of immune-mediated myositis
S Khan, H Haegal, A Holleinstein, C Wandel, D Asher, D Griffin, R Potter, I Moeller, T Singh, L Rodino-Klapac

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
03:30 PM
Duration 30mins Ballroom C3
RAINBOWFISH: Primary efficacy and safety data in risdiplam▼-treated infants with presymptomatic spinal muscular atrophy SMA
RS Finkel, MA Farrar, L Servais, D Vlodavets, E Zanoteli, M Al-Muhaizea, A Prufer, L Nelson, B Jaber, K Gorni, H Kletzl, L Palfreeman, E Gaki, M Rabbia, D Summers, P Fontoura, E Bertini

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
03:30 PM
Duration 1hr Charleston, USA
Long-term comparative efficacy and safety of risdiplam▼ versus nusinersen in children with Type 1 SMA
N Hawkins, R Evans, G Sajeev, A Mahajan, DA Scott, J Nam, CS Sutherland, C Kokaliaris

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 1hr Charleston, USA
Real-world treatment with risdiplam▼ in adults with SMA: A multicenter study
CJ Guittari, S Candrilli, LS Miles, A Simpson, S Shapouri

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 1hr Charleston, USA
Risdiplam▼ experience following onasemnogene abeparvovec in individuals with spinal muscular atrophy: a multicenter case series
Kuntz NL, Svoboda MD, Leon-Astudillo C, Byrne B, Krueger J, Kwon JM, Sieburg C, Castro D

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar